Wendell Wierenga

Wendell D.
Wierenga is an Independent Director at Cytokinetics, Inc. since 2011 and an Independent Director at Dermata Therapeutics, Inc. since 2016.
Former roles include Chairman at Crinetics Pharmaceuticals, Inc. from 2015 to 2026, Chief Executive Officer at Syrrx, Inc. from 1999 to 2004, Independent Director at Onyx Pharmaceuticals, Inc. from 2011 to 2013, Independent Director at Apricus Biosciences, Inc. from 2014 to 2019, Director at Aspira Women's Health, Inc. from 2003 to 2006, Independent Director at XenoPort, Inc. from 2011 to 2016, Independent Director at OCERA Therapeutics LLC from 2013 to 2017, Independent Director at Anacor Pharmaceuticals LLC from 2015 to 2016, Independent Director at Concert Pharmaceuticals, Inc. from 2014 to 2019, Vice President-Medtech Ventures at Warner-Lambert Co. from 1992 to 2000, Executive Vice President-Research & Development at Santarus, Inc. from 2011 to 2014, Senior Vice President-Research at Parke-Davis Pharmaceutical Research, Inc. from 1990 to 2000, Executive Vice President-Research & Development at Neurocrine Biosciences, Inc. from 2004 to 2006, Senior VP-Worldwide Pharmaceutical Sciences at Pfizer Inc. from 1990 to 2000, and Executive Vice President-Research & Development at Ambit Biosciences Corp.
from 2007 to 2011.
Also held titles of Executive Director-Discovery Research at Pharmacia & Upjohn, Inc. and The Upjohn Co., and Director at Patara Pharma LLC and SRI International.
Education includes a doctorate from Stanford University and an undergraduate degree from Hope College.